ArticlePharmaceutics2020
Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics.
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Nanoencapsulated senotherapeutic compounds targeting connexin-43 for enhanced wound healing.iScience · 2026Article
- Mechanistic Insights into Sphingomyelin Nanoemulsions as Drug Delivery Systems for Non-Small Cell Lung Cancer Therapy.Pharmaceutics · 2025Article
- Development and Characterization of Magnetic Nanoemulsion-Based Senolytic Peptides for Osteoarthritis Treatment.International journal of molecular sciences · 2025Article
- Methods of miRNA delivery and possibilities of their application in neuro-oncology.Non-coding RNA research · 2023Review
- Lipid carriers for mRNA delivery.Acta pharmaceutica Sinica. B · 2023Review
- Engineered Lipidic Nanomaterials Inspired by Sphingomyelin Metabolism for Cancer Therapy.Molecules (Basel, Switzerland) · 2023Review
- Roles and mechanisms of exosomal microRNAs in viral infections.Archives of virology · 2023Review
- Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents.International journal of nanomedicine · 2023Review
- Three Pathways of Cancer Cachexia: Inflammation, Changes in Adipose Tissue and Loss of Muscle Mass-The Role of miRNAs.Journal of personalized medicine · 2022Review
- Role of Nano-miRNAs in Diagnostics and Therapeutics.International journal of molecular sciences · 2022Review
- The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA.Pharmaceutics · 2022Review
- The nutritional functions of dietary sphingomyelin and its applications in food.Frontiers in nutrition · 2022Review
- Zebrafish as a platform to evaluate the potential of lipidic nanoemulsions for gene therapy in cancer.Frontiers in pharmacology · 2022Article
- Manganese Ferrite Nanoparticles Encapsulated into Vitamin E/Sphingomyelin Nanoemulsions as Contrast Agents for High-Sensitive Magnetic Resonance Imaging.Advanced healthcare materials · 2021Article
- Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem.Pharmaceutics · 2021Article
- Bioactive Lipids and Their Derivatives in Biomedical Applications.Biomolecules & therapeutics · 2021Review
- Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer.Scientific reports · 2021Article
- Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment.Advanced healthcare materials · 2021Review
- Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model.Scientific reports · 2021Article
- Non-Viral Gene Delivery Systems.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Gene replacement therapy with oncosuppressor microRNAs (miRNAs) is a promising alternative to interfere with cancer progression. However, miRNAs are highly inefficient in a biological environment, hampering a successful translation to clinics. Nanotechnology can tackle this drawback by providing delivery systems able to efficiently deliver them to cancer cells. Thus, the objective of this work was to develop biocompatible nanosystems based on sphingomyelin (SM) for the intracellular delivery of miRNAs to colorectal cancer cells. We pursued two different approaches to select the most appropriate composition for miRNA delivery. On the one hand, we prepared sphingomyelin-based nanosystems (SNs) that incorporate the cationic lipid stearylamine (ST) to support the association of miRNA by the establishment of electrostatic interactions (SNs-ST). On the other hand, the cationic surfactant (DOTAP) was used to preform lipidic complexes with miRNA (Lpx), which were further encapsulated into SNs (SNs-Lpx). Restitution of miRNA145 levels after transfection with SNs-Lpx was related to the strongest anticancer effect in terms of tumor proliferation, colony forming, and migration capacity assays. Altogether, our results suggest that SNs have the potential for miRNA delivery to develop innovative anticancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.